-
EP1948798
European procedure
Extract from the Register of European Patents
EP About this file: EP1948798
| EP1948798 - ANTI-ALPHA2 INTEGRIN ANTIBODIES AND THEIR USES [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 05.02.2016 Database last updated on 19.10.2024 | Most recent event Tooltip | 05.02.2016 | No opposition filed within time limit | published on 09.03.2016 [2016/10] | Applicant(s) | For all designated states Glenmark Pharmaceuticals S.A. Chemin de la Combeta, 5 2300 La Chaux-de-Fonds / CH | [2008/31] | Inventor(s) | 01 /
LAZARIDES, Elias 7260 Romero Drive La Jolla, CA 92037 / US | 02 /
WOODS, Catherine 7260 Romero Drive La Jolla, CA 92037 / US | 03 /
BERNARD, Mark A. 20 Swanson Road Framingham, Massachusetts 01701 / US | [2011/41] |
| Former [2008/41] | 01 /
LAZARIDES, Elias 7260 Romero Drive La Jolla, CA 92037 / US | ||
| 02 /
WOODS, Catherine 7260 Romero Drive La Jolla, CA 92037 / US | |||
| 03 /
BERNARD, Mark 20 Swanson Road Farmingham, Massachusetts 01701 / US | |||
| Former [2008/31] | 01 /
LAZARIDES, Elias 7260 Romero Drive La Jolla, CA 92037 / US | ||
| 02 /
WOODS, Catherine 7260 Romero Drive La Jolla, CA 92037 / US | |||
| 03 /
BERNARD, Mark 535 Gabriel Ct. Walnut Creek, CA 94597 / US | Representative(s) | Latscha Schöllhorn Partner AG Austrasse 24 4051 Basel / CH | [2015/14] |
| Former [2014/43] | Latscha Schöllhorn Partner Latscha Schöllhorn Partner AG Austrasse 24 4051 Basel / CH | ||
| Former [2012/34] | Schöllhorn, Andreas, et al Latscha Schöllhorn Partner AG Aeschenvorstadt 55 4051 Basel / CH | ||
| Former [2009/10] | KATZAROV S.A. Basel Office Steinenring 8 4051 Basel / CH | ||
| Former [2008/31] | Schnappauf, Georg, et al Dr. Volker Vossius Patent- und Rechtsanwaltskanzlei Geibelstrasse 6 81679 München / DE | Application number, filing date | 06804739.8 | 17.11.2006 | [2008/31] | WO2006CA01876 | Priority number, date | US20050738303P | 18.11.2005 Original published format: US 738303 P | [2008/31] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2007056858 | Date: | 24.05.2007 | Language: | EN | [2007/21] | Type: | A1 Application with search report | No.: | EP1948798 | Date: | 30.07.2008 | Language: | EN | The application published by WIPO in one of the EPO official languages on 24.05.2007 takes the place of the publication of the European patent application. | [2008/31] | Type: | B1 Patent specification | No.: | EP1948798 | Date: | 01.04.2015 | Language: | EN | [2015/14] | Search report(s) | International search report - published on: | CA | 24.05.2007 | (Supplementary) European search report - dispatched on: | EP | 22.01.2010 | Classification | IPC: | C12N15/13, A61K39/395, A61P19/00, A61P35/00, A61P37/02, C07K14/705, C07K14/78, C07K16/28, C12N15/63, C12N5/10, C12P21/08, G01N33/53, G01N33/543, G01N33/566 | [2008/31] | CPC: |
C07K16/2842 (EP,US);
C07K16/28 (KR);
A61K39/395 (KR);
A61K39/3955 (US);
A61K47/6849 (EP,US);
A61P1/04 (EP);
A61P17/00 (EP);
A61P17/06 (EP);
A61P19/00 (EP);
A61P19/02 (EP);
A61P25/00 (EP);
A61P25/02 (EP);
A61P27/02 (EP);
A61P29/00 (EP);
A61P3/10 (EP);
A61P35/00 (EP);
A61P37/00 (EP);
A61P37/02 (EP);
A61P37/06 (EP);
A61P43/00 (EP);
A61P9/00 (EP);
C07K14/7055 (US);
C07K14/78 (KR);
C12N15/11 (KR);
G01N33/6872 (US);
G01N33/6893 (EP,US);
A61K2039/505 (EP,US);
C07K2317/24 (EP,US);
C07K2317/34 (EP,US);
C07K2317/52 (EP,US);
C07K2317/56 (EP,US);
C07K2317/567 (EP,US);
C07K2317/76 (EP,US);
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2008/31] | Extension states | AL | 15.05.2008 | BA | 15.05.2008 | HR | 15.05.2008 | MK | 15.05.2008 | RS | 15.05.2008 | Title | German: | ANTI-ALPHA2-INTEGRIN-ANTIKÖRPER UND DEREN VERWENDUNGEN | [2008/31] | English: | ANTI-ALPHA2 INTEGRIN ANTIBODIES AND THEIR USES | [2008/31] | French: | ANTICORPS ANTI-INTEGRINE ALPHA-2 ET LEURS UTILISATIONS | [2008/40] |
| Former [2008/31] | ANTICORPS ANTI-INTÉGRINE ALPHA-2 ET LEURS UTILISATIONS | Entry into regional phase | 07.05.2008 | National basic fee paid | 07.05.2008 | Search fee paid | 07.05.2008 | Designation fee(s) paid | 07.05.2008 | Examination fee paid | Examination procedure | 07.05.2008 | Examination requested [2008/31] | 19.04.2010 | Amendment by applicant (claims and/or description) | 07.11.2011 | Despatch of a communication from the examining division (Time limit: M04) | 02.03.2012 | Reply to a communication from the examining division | 31.10.2012 | Despatch of a communication from the examining division (Time limit: M02) | 05.12.2012 | Reply to a communication from the examining division | 05.01.2014 | Observations by third parties | 20.05.2014 | Communication of intention to grant the patent | 15.09.2014 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 09.10.2014 | Communication of intention to grant the patent | 05.02.2015 | Observations by third parties | 11.02.2015 | Fee for grant paid | 11.02.2015 | Fee for publishing/printing paid | 11.02.2015 | Receipt of the translation of the claim(s) | Divisional application(s) | EP15162049.9 / EP3023497 | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 07.11.2011 | Opposition(s) | 05.01.2016 | No opposition filed within time limit [2016/10] | Fees paid | Renewal fee | 07.11.2008 | Renewal fee patent year 03 | 14.10.2009 | Renewal fee patent year 04 | 29.09.2010 | Renewal fee patent year 05 | 18.10.2011 | Renewal fee patent year 06 | 14.11.2012 | Renewal fee patent year 07 | 28.11.2013 | Renewal fee patent year 08 | 25.11.2014 | Renewal fee patent year 09 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]EP0759302 (KANEBO LTD [JP]) [Y] 45-64 * pages 3-5; examples 1,2; claims 1-5 *; | [Y]US2004162413 (WATKINS JEFFRY D [US], et al) [Y] 1-64,67-69 * the whole document * * in particular examples *; | [XY] - HANGAN DOLORES ET AL, "Integrin VLA-2 (alpha-2-beta-1) function in postextravasation movement of human rhabdomyosarcoma RD cells in the liver", CANCER RESEARCH, (1996), vol. 56, no. 13, ISSN 0008-5472, pages 3142 - 3149, XP009126568 [X] 65-66 * abstract * * page 3143 * [Y] 1-64,67-69 | [Y] - MAN SUNG CO ET AL, "HUMANIZED ANTIBODIES FOR THERAPY", NATURE, NATURE PUBLISHING GROUP, LONDON, UK, (19910606), vol. 351, no. 6326, ISSN 0028-0836, page 501/502, XP001206303 [Y] 1-64,67-69 * the whole document * DOI: http://dx.doi.org/10.1038/351501a0 | [Y] - FOUGEROLLES DE A R ET AL, "Regulation of inflammation by collagen-binding integrins alpha1beta1 and alpha2beta1 in models of hypersensitivity and arthritis", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, (20000301), vol. 105, no. 6, ISSN 0021-9738, pages 721 - 729, XP002310288 [Y] 1-64,67-69 * the whole document * * page 722, column LEFT * DOI: http://dx.doi.org/10.1172/JCI7911 | [Y] - YOSHINO KOHICHIRO ET AL, "Suppression of murine collagen-induced arthritis with monoclonal antibody against alpha2beta1 integrin", ARTHRITIS AND RHEUMATISM, LIPPINCOTT, PHILADELPHIA, US, (19971112), vol. 40, no. 9 Suppl, ISSN 0004-3591, page S97, XP009126647 [Y] 1-64,67-69 * abstract * | [A] - LITTLE M ET AL, "Of mice and men: hybridoma and recombinant antibodies", IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, (20000801), vol. 21, no. 8, ISSN 0167-5699, pages 364 - 370, XP004215163 [A] 1-6,8-13,67-69 * page 367, column LEFT; figure 3 * DOI: http://dx.doi.org/10.1016/S0167-5699(00)01668-6 | [A] - DAVIES J ET AL, "Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding", IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, (19960901), vol. 2, no. 3, ISSN 1380-2933, pages 169 - 179, XP004070292 [A] 1,8,67-69 * abstract * DOI: http://dx.doi.org/10.1016/S1380-2933(96)00045-0 | [A] - HOLT L J ET AL, "Domain antibodies: proteins for therapy", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, (20031101), vol. 21, no. 11, ISSN 0167-7799, pages 484 - 490, XP004467495 [A] 1,8,67-69 * abstract * DOI: http://dx.doi.org/10.1016/j.tibtech.2003.08.007 | International search | [X]EP0759302 (KANEBO LTD [JP]); | [XP]WO2006022682 (APPLERA CORP [US], et al); | [X] - SCHOOLMEESTER A. ET AL., "Monoclonal antibody IAC-1 is specific for activated alpha2beta1 and binds to amino acids 199 to 201 of the integrin alpha2 I-domain", BLOOD, (20040715), vol. 104, pages 390 - 396, XP003013249 DOI: http://dx.doi.org/10.1182/blood-2003-12-4224 | [X] - TUCKWELL D.S. ET AL., "Monoclonal antibodies identify residues 199-216 of the integrin alpha2 vWFA domain as a functionally important region within alpha2beta1", BIOCHEM. J., (200009), vol. 350, pages 485 - 493, XP003013250 DOI: http://dx.doi.org/10.1042/0264-6021:3500485 | [A] - KAMATA T. ET AL., "Identification of putative ligand binding sites within I domain of integrin alpha2beta1 (VLA-2, CD49b/CD29)", J. BIOL. CHEM., (199404), vol. 269, pages 9659 - 9663, XP003013251 | [A] - ESTAVILLO D. ET AL., "Functional analysis of a recombinant glycoprotein Ia/IIa (Integrin alpha2beta1) I domain that inhibits platelet adhesion to collagen and endothelial matrix under flow conditions", J. BIOL. CHEM., (199912), vol. 274, pages 35921 - 35926, XP003013252 DOI: http://dx.doi.org/10.1074/jbc.274.50.35921 | [A] - SMITH C. ET AL., "Mapping the collagen-binding site in the I domain of the glycoprotein Ia/IIa (Integrin alpha2beta1)", J. BIOL. CHEM., (20000211), vol. 275, pages 4205 - 4209, XP003013253 DOI: http://dx.doi.org/10.1074/jbc.275.6.4205 | by applicant | US5855888 | EP1121151 | US6596276 | US6780603 | US2008267978 |